Natco Pharma rose 1.96% to Rs 808 at 11:06 IST on BSE after consolidated net profit rose 28.57% to Rs 27 crore on 1.57% decline in revenue to Rs 188 crore in Q2 September 2013 over Q2 September 2012.
The Q2 result was announced after market hours on Thursday, 14 November 2013. The stock market was closed on Friday, 15 November 2013 on account of Muharram.
Meanwhile, the S&P BSE Sensex was up 297.68 points or 1.46% at 20,697.10.
On BSE, 34,000 shares were traded in the counter as against average daily volume of 18,490 shares in the past one quarter.
The stock hit a high of Rs 824.20 and a low of Rs 774.40 so far during the day. The stock had hit a record high of Rs 826 on Thursday, 14 November 2013. The stock had hit a 52-week low of Rs 390 on 16 May 2013.
The stock had outperformed the market over the past one month till 14 November 2013, surging 16.28% compared with the Sensex's 1.01% fall. The scrip had also outperformed the market in past one quarter, jumping 27.58% as against Sensex's 5.33% rise.
The small-cap company has equity capital of Rs 31.37 crore. Face value per share is Rs 10.
Natco Pharma's consolidated EBITDA (earnings before interest, taxation, depreciation and amortization) margins have expanded to 31% of the revenue in Q2 September 2013, from 26% of revenue in Q2 September 2012.
Natco Pharma manufactures generic dosage forms, bulk actives and intermediates for the Indian and international markets.
Powered by Capital Market - Live News
